The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.

Journal article

Over-expression of the proto-oncogene Akt/PKB has been demonstrated in some neuroendocrine tumor models. Akt may activate downstream proteins such as mTOR and p70S6K, inducing tumor proliferation. The rapamycin-derivative RAD001, everolimus, interacts with this pathway by antagonizing mTOR, but its effects on neuroendocrine tumors are largely unknown. We explored the mechanism of action of RAD001 on cell proliferation, hormonal secretion and on Akt/mTOR/p70S6K pathway activation, in a human m...

Expand abstract

Authors: Grozinsky-Glasberg, S; Rubinfeld, H; Nordenberg, Y; Gorshtein, A; Praiss, M

• Publication status: Published
• Journal: Molecular and cellular endocrinology
• Volume: 315
• Issue: 1-2
• Pages: 87-94
• Publication date: 2010-02-01
• DOI: 10.1016/j.mce.2009.09.027
• EISSN: 1872-8057
• ISSN: 0303-7207
• Language: English
• Keywords: Immunosuppressive Agents; Cell Survival; Ribosomal Protein S6 Kinases, 70-kDa; Cell Cycle; Protein-Serine-Threonine Kinases; Aged; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Proto-Oncogene Proteins c-akt; Calcitonin; Middle Aged; Phosphorylation; Intracellular Signaling Peptides and Proteins; Thyroid Neoplasms; Sirolimus; Male; Thyroid Gland; Carcinoembryonic Antigen; Humans